
Sign up to save your podcasts
Or


As recently as a few years ago, the idea of a self-administered injection that would deliver proven weight-loss results might have sounded fantastical. Today, these medications are a reality and a global phenomenon; hailed in many quarters as “miracle drugs" for their success in treating obesity and diabetes. They do this by replicating a gut hormone called GLP‑1, which tells the brain you’ve eaten enough and nudges the pancreas to release insulin; and this hormone was discovered and decoded thanks to years of work by today's guest. Jens Juul Holst is a Professor of Medical Physiology and Biomedical Sciences at the University of Copenhagen. His efforts laid the groundwork for today’s weight loss jabs, earning him a slew of high-profile accolades and awards. Now it seems they might not only have positive impacts on obesity and diabetes, but also other health issues... But alongside the big success comes some big questions: including concerns over side effects, weight regain post-treatment, the black market in such drugs, and their cost and accessibility. In a frank conversation with Professor Jim Al-Khalili, Jens address these issues and shares his hopes for the future of GLP-1-focused research.
By BBC World Service4.4
940940 ratings
As recently as a few years ago, the idea of a self-administered injection that would deliver proven weight-loss results might have sounded fantastical. Today, these medications are a reality and a global phenomenon; hailed in many quarters as “miracle drugs" for their success in treating obesity and diabetes. They do this by replicating a gut hormone called GLP‑1, which tells the brain you’ve eaten enough and nudges the pancreas to release insulin; and this hormone was discovered and decoded thanks to years of work by today's guest. Jens Juul Holst is a Professor of Medical Physiology and Biomedical Sciences at the University of Copenhagen. His efforts laid the groundwork for today’s weight loss jabs, earning him a slew of high-profile accolades and awards. Now it seems they might not only have positive impacts on obesity and diabetes, but also other health issues... But alongside the big success comes some big questions: including concerns over side effects, weight regain post-treatment, the black market in such drugs, and their cost and accessibility. In a frank conversation with Professor Jim Al-Khalili, Jens address these issues and shares his hopes for the future of GLP-1-focused research.

7,699 Listeners

883 Listeners

1,054 Listeners

5,544 Listeners

1,798 Listeners

1,761 Listeners

1,034 Listeners

2,008 Listeners

601 Listeners

769 Listeners

91 Listeners

421 Listeners

415 Listeners

822 Listeners

762 Listeners

729 Listeners

229 Listeners

363 Listeners

474 Listeners

241 Listeners

3,168 Listeners

733 Listeners

113 Listeners

1,004 Listeners